When will a Somatuline generic be available in the US?
Somatuline (lanreotide) has a US patent and exclusivity timeline that controls when an approved generic can launch. Based on the US patent/exclusivity periods discussed for lanreotide/Somatuline, the expected earliest US generic launch timing is tied to patent expiry around 2030 (with the possibility of exclusivity-related delays depending on the specific Orange Book entries and any FDA exclusivity extensions). [1][2]
What exactly is “Somatuline,” and which product drives the generic timing?
“Somatuline” can refer to different formulations of lanreotide. The generic timing depends on which specific Somatuline product strength/formulation is being compared to the listed Orange Book patents (for example, long-acting injections with different dosing strengths). If you are tracking launch for a specific NDC/strength, you need to match that to the correct patents and exclusivity listed for that exact product. [2]
How do patents vs FDA exclusivity affect the launch date?
Generic availability in the US is usually governed by two layers:
1) Patent expiry listed in the FDA’s Orange Book, which stops ANDA approval/marketing until the relevant protections end.
2) FDA exclusivity (for example, periods tied to product approval pathways), which can extend availability even after some patents expire.
So even if one patent ends, exclusivity or other remaining patents can still delay launch. [1][2]
Where can you check the most precise “earliest date” for a specific Somatuline NDC?
The most precise answer comes from the FDA Orange Book listing for the exact Somatuline product and strength, including the “expires” dates for each listed patent and any exclusivity. The secondary summary timelines online often simplify this, so Orange Book is what confirms the specific earliest affected date for that NDC. [2]
Could a generic launch earlier than the summarized 2030 date?
If a manufacturer is able to “carve out” around specific claims (for example, via a successful patent challenge) or if certain patents expire earlier than others for that exact product/formulation, the effective earliest launch date could differ from a single headline estimate. Those outcomes require looking at the Orange Book patent-by-patent schedule for the exact Somatuline listing. [2]
Sources
[1] https://www.drugs.com/patent-expirations/lanreotide.html
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm